Hace algún tiempo en un foro americano había oído a un compañero hablar de que él se inyectaba su HRT (Terapia de sustitución hormonal en base de testosterona) vía subcutánea porque no le gustaba inyectarse IM. Sorprendido le pregunté que cómo hacía esa locura, y me dijo que había varios estudios clínicos que demostraban que no había diferencia. Y hoy que he tenido un rato me he puesto a investigar un poquito, os dejo los enlaces.
ADVERTENCIA: NO estoy diciendo que se pueda hacer un ciclo vía subcutánea, simplemente os pongo la información que he encontrado.
According to convention if we inject oil-based AAS into the fat layer beneath the skin and above the muscle (subcutaneous) it will impair absorption and could delay dissapation of drugs for many weeks or months. New research conducted at the Royal Victoria Hospital in Canada at the endocrine clinic tested the viability of subcutaneous shots.
The study involved 22 patients who were using the clinic for testosterone replacement therapy. The AAS was testosterone enanthate.
The subjects were instructed to self-administer their testosterone subcutaneously once per week.
The same 1ml that would have been injected once every 2 weeks was divided up into .5ml weekly injections.
Blood tests which were conducted periodically throughout the 1 year investigation were suprisingly and unquestionably consistent. For exactly 100% of patients enrolled, testosterone levels remained in the physiological (normal) range for the entire duration of the study. This included both peak and trough levels (high & low during each week). Furthermore injections were extremely well tolerated. Each patient took over 50 injections and not one single adverse reactionn was noticed at the injection site.
The investigation concluded that not only was subcutaneous testosterone enanthate a viable option as far as drug release , but it was safe, cheap and far more comfortable for their patients compared to intramuscular injections.
Saudi Med J, 2006 Dec;27(12):1843-6
[Subcutaneous administration of testosterone. A pilot study report]
Hay otro estudio, que no he podido encontrar, del qual os dejo el resumen.
Subcutaneous Administration of Testosterone
These two articles shows that subc injections of AAS are quite viable alternative for IM injections.
STABLE TESTOSTERONE LEVELS ACHIEVED WITH SUBCUTANEOUS TESTOSTERONE INJECTIONS
M.B. Greenspan, C.M. Chang
Division of Urology, Department of Surgery, McMaster University,
Hamilton, ON, Canada
The preferred technique of androgen replacement has been intramuscular (IM) testosterone, but wide variations in testosterone levels are often seen
. Subcutaneous (SC) testosterone injection is a novel approach; however, its physiological effects are unclear.
We therefore investigated the sustainability of stable testosterone levels using SC therapy.
Patients and methods: Between May and September 2005, we conducted a small pilot study involving 10 male patients with symptomatic late-onset hypogonadism. Every patient had been stable on TE 200 mg IM for 41 year. Patients were instructed to self-inject with testosterone enanthate (TE) 100 mg SC (DELATESTRYL 200 mg/cc, Theramed Corp, Canada) into the anterior abdomen once weekly. Some patients were down-titrated to 50 mg based on their total testosterone (T) at 4 weeks. Informed consent was obtained as SC testosterone administration is not officially approved by Health Canada. T levels were measured before and 24 hours after injection during weeks 1, 2, 3, and 4, and 96 hours after injection in week 6 and 8. At week 12, PSA, CBC, and T levels were measured however; the week 12 data are still being collected. Results: Prior to initiation of SC therapy, T was 19.14+3.48 nmol/l, hemoglobin 15.8+1.3 g/dl, hematocrit 0.47+0.02, and PSA 1.05+0.65 ng/ml. During the first 4 weeks, there was a steady increase in pre-injection T from 19.14+3.48 to 23.89+9.15 nmol/l (p¼0.1). However, after 8 weeks the post-injection T (25.77+7.67 nmol/l) remained similar to that of week 1 (27.46+12.91 nmol/l).
Patients tolerated this therapy with no adverse effects.
Conclusions: A once-week SC injection of 50–100 mg of TE appears to achieve sustainable and stable levels of physiological T. This technique offers fewer physician visits and the use of smaller quantity of medication, thus lower costs. However, the long term clinical and physiological effects of this therapy need further evaluation.
CONCLUSION: Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. This is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route.
Parece ser que no hay diferencia en la asimilación del medicamento y como véis NO se reportó NINGÚN CASO de efectos adversos -ni abscesos siquiera-. Éso sí, es necesario pincharse en cantidades menores, mayores veces a la semana.
(http://www.steroidology.com/forum/testosterone-replacement-therapy/592889-injecting-supplemental-doses-testosterone-subcutaneously.html) os dejo la experiencia de un chaval de otro foro americano.